<DOC>
	<DOC>NCT02724618</DOC>
	<brief_summary>There is a growing body of evidence exploring the role of curcumin as a radioprotector against radiation-induced injury in normal tissues as well as a radiosensitizer in tumor cells. The aim of this study is to determine the efficacy of oral nanocurcumin in prostate cancer patients undergoing radiotherapy.</brief_summary>
	<brief_title>Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>Histologically confirmed adenocarcinoma of the prostate Candidate for External Beam Radiotherapy ECOG performance status 02 Patients with Metastatic Prostate Cancer Patients with Kidney &amp; Liver dysfunction Gastrointestinal disorders such as IBD, reflux and peptic ulcers Any adverse reaction to curcumin</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Curcumin</keyword>
	<keyword>Protection, Radiation</keyword>
	<keyword>Controlled Clinical Trials, Randomized</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>